- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04224493
Estudo em indivíduos com linfoma folicular recidivante/refratário (SYMPHONY-1)
SYMPHONY-1: Um estudo adaptativo de biomarcadores de fase 1b/3, duplo-cego, randomizado, controlado ativamente, de 3 estágios, de tazemetostat ou placebo em combinação com lenalidomida mais rituximabe em indivíduos com linfoma folicular recidivante/refratário
The participants of this study would have relapsed/refractory follicular lymphoma.
Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works.
Stage 1 of this trial studied the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed.
Stages 2 and 3 were designed to evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment. However, following an urgent safety measure, treatment with tazemetostat and placebo was discontinued, enrollment was stopped, and the study was unblinded. As a result, post-urgent safety measure analyses are descriptive in nature.
Visão geral do estudo
Status
Descrição detalhada
In Stage 2, participants were enrolled into study cohorts based on whether they have a specific genetic mutation in the EZH2 gene. All participants received treatment in 28-day cycles. After 12 cycles, they continued with maintenance treatment using either the study drug or placebo, depending on their original treatment group. However, following the urgent safety measure, treatment was permanently discontinued and no further interventional procedures are being conducted.
The study included participants with and without the mutation in EZH2 gene. Enrollment was to be completed separately for each group. In China, some participants also had extra blood tests to better understand how the drug behaves in the body; no further pharmacokinetic data are being collected following the urgent safety measure.
Stage 3 focuses on long-term safety monitoring after the urgent safety measure. Participants treated with tazemetostat will be followed for up to 5 years after the last dose of tazemetostat
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha
- Vivantes Klinikum am Urban Hämatologie und Onkologie
-
Kiel, Alemanha
- University Medical Center Schleswig Holstein
-
-
Baden-Wurttemberg
-
Schwäbisch Hall, Baden-Wurttemberg, Alemanha, 74523
- Diakoneo Diak Schwaebisch Hall gGmbH
-
-
Bavaria
-
München, Bavaria, Alemanha, 81377
- Klinikum Der Universität München AöR
-
-
Hesse
-
Mainz, Hesse, Alemanha, 55131
- Universitätsmedizin Mainz
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Alemanha, 53127
- Universitaetsklinikum Bonn AöR
-
Mönchengladbach, North Rhine-Westphalia, Alemanha, 41063
- Kliniken Maria Hilf GmbH
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Alemanha, 24116
- Städt. Krankenhaus Kiel
-
-
-
-
-
Adelaide, Austrália
- GenesisCare - St Andrew's
-
Frankston, Austrália
- Peninsula Health - Frankston
-
Hobart, Austrália
- Royal Hobart Hospital
-
Southport, Austrália
- Gold Coast University Hosptial
-
-
South Australia
-
Adelaide, South Australia, Austrália, 5000
- Royal Adelaide Hospital
-
Bedford Park, South Australia, Austrália, 5042
- Flinders Medical Centre
-
-
Victoria
-
Clayton, Victoria, Austrália, 3168
- Monash Health
-
Geelong, Victoria, Austrália, 3220
- Barwon Health, University Hospital Geelong
-
-
Western Australia
-
Nedlands, Western Australia, Austrália, 6009
- Hollywood Private Hospital
-
-
-
-
-
Ceará, Brasil
- Hospital Haroldo Juacaba - Instituto do Cancer do Ceara
-
Curitiba, Brasil
- Hospital Santa Cruz
-
Goiânia, Brasil
- HC-UFG - Hospital das CLINICAS da Universidade Federal de Go
-
Ijuí, Brasil
- Association Hospital de Caridade de Iju
-
Natal, Brasil
- Liga Norte Riograndense Contra o Cancer
-
Porto Alegre, Brasil
- Hospital de Clinicas de Porto Alegre - Centro de Pesquisa Clinica
-
Recife, Brasil
- Instituto D'Or de Pesquisa e Ensino- Recife
-
Rio de Janeiro, Brasil
- Instituto de Psiquiatria - UFRJ
-
Rio de Janeiro, Brasil
- Instituto Nacional de Câncer - INCA
-
São Paulo, Brasil
- Fundacao Antonio Prudente - Hospital A.C.Camargo Cancer Center
-
São Paulo, Brasil
- Hospital Alemao Oswaldo Cruz (HAOC)
-
São Paulo, Brasil
- Instituto de Oncologia e Hematologia - HEMOMED
-
São Paulo, Brasil
- Irmandade Santa Casa de Misericordia de Sao Paulo
-
São Paulo, Brasil
- Instituto D'or de Pesquisa e Ensino
-
-
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Bélgica, 9000
- Universitair Ziekenhuis Gent
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Bélgica, 3000
- UZ Leuven - Campus Gasthuisberg
-
-
-
-
-
Nova Scotia, Canadá
- Nova Scotia Health Centre for Clinical Research
-
Ottawa, Canadá
- Sunnybrook Health Sciences Centre Odette Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- University Health Network Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canadá, H3T 1E2
- Sir Mortimer B Davis/Jewish General Hospital
-
Montreal, Quebec, Canadá, H2X 3E4
- Centre Hospitalier de l'Universite de Montreal (CHUM)
-
-
-
-
-
Beijing, China, 100191
- Peking University Third Hospital
-
Hangzhou, China
- The First Affiliated Hospital Zhejiang University School of Medicine
-
Hangzhou, China
- Tongji Hospital of Tongji Medical College of HUST
-
Nanchang, China
- Jiangxi Cancer Hospital
-
Shandong, China
- Shandong Cancer Hospital
-
Shanghai, China
- Tongji Hospital of Tongji University
-
Sichuan, China
- Sichuan Provincial People's Hospital
-
Tianjin, China, 300060
- Tianjin Medical University Cancer Institute & Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Fujian Medical University Union Hospital
-
Xiamen, Fujian, China, 361003
- The First Affiliated Hospital of Xiamen University
-
-
Guizhou
-
Guiyang, Guizhou, China, 550004
- The Affiliated Hospital of Guizhou Medical University
-
-
Hangzhou
-
Zhejiang, Hangzhou, China, 310000
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050011
- The Fourth Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, China, 45008
- Henan Cancer Hospital
-
Zhengzhou, Henan, China, 450008
- Henan Provincial People's Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Cancer Hospital
-
-
Jinlin
-
Changchun, Jinlin, China, 130021
- The First Bethune Hospital of Jilin University
-
-
Shandong
-
Qingdao, Shandong, China, 266071
- The Affiliated Hospital of Qingdao University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 20025
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
-
Shanxi
-
Taiyuan, Shanxi, China, 30032
- Shanxi Bethune Hospital
-
-
-
-
-
Singapore, Cingapura
- Tan Tock Seng Hospital
-
Singapore, Cingapura
- National Cancer Center Singapore
-
-
-
-
-
Busan, Coréia do Sul
- Pusan National University Hospital
-
Incheon, Coréia do Sul
- Gachon University Gil Medical Center
-
Suwon, Coréia do Sul
- Ajou University Hospital
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Coréia do Sul, 03080
- Seoul National University Hospital
-
-
Seoul Teugbyeolsi [Seoul-T'ukp
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Coréia do Sul, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Coréia do Sul, 06351
- Samsung Medical Center
-
-
Seoul Teugbyeolsi [Seoul-T'ukp]
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Coréia do Sul, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
-
-
-
Barcelona, Espanha, 08003
- Hospital Del Mar
-
El Palmar, Espanha
- Hospital Virgen de la Arrixaca
-
Madrid, Espanha, 28046
- Hospital Universitario La Paz
-
Madrid, Espanha, 28031
- Hospital Univ. Infanta Leonor
-
Madrid, Espanha
- Clínica Universidad de Navarra
-
Pamplona, Espanha
- C.H. de Navarra
-
Salamanca, Espanha, 37007
- Hospital Universitario de Salamanca
-
Seville, Espanha, 41014
- Hospital Universitario Nuestra Señora de Valme
-
Seville, Espanha
- Hospital Universitario Virgen De La Macarena
-
-
Cataluny
-
Barcelona, Cataluny, Espanha, 08035
- Hospital Universitari Vall d'Hebrón
-
-
Málaga
-
Marbella, Málaga, Espanha, 29603
- Hospital Costa del Sol
-
-
-
-
Alabama
-
Mobile, Alabama, Estados Unidos, 36608
- Southern Cancer Center
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85704
- Arizona Oncology Associates - Tuscon-Rusadill Road
-
-
California
-
Cerritos, California, Estados Unidos, 90703
- TOI - Clinical Research
-
Clovis, California, Estados Unidos, 93611
- UCSF Fresno
-
La Jolla, California, Estados Unidos, 92093
- UC San Diego Health Sciences
-
Santa Monica, California, Estados Unidos, 90404
- UCLA Clinical Research Unit Hematology/Oncology
-
-
Colorado
-
Boulder, Colorado, Estados Unidos, 80303
- Rocky Mountain Cancer Centers (RMCC) - Boulder
-
Grand Junction, Colorado, Estados Unidos, 81501
- St. Mary's Hospital and Regional Medical Center - St. Mary's
-
-
Florida
-
Fleming Island, Florida, Estados Unidos, 32003
- Cancer Specialists of North Florida
-
Fort Myers, Florida, Estados Unidos, 33908
- Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center
-
Jacksonville, Florida, Estados Unidos, 32224
- Mayo Clinic
-
Ocala, Florida, Estados Unidos, 34474
- Florida Cancer Affiliates/Ocala Oncology - Clinic
-
Plantation, Florida, Estados Unidos, 33322
- BRCR Medical Center, INC
-
St. Petersburg, Florida, Estados Unidos, 33705
- Florida Cancer Specialists
-
Tallahassee, Florida, Estados Unidos, 32308
- Florida Cancer Specialists - Panhandle
-
Tampa, Florida, Estados Unidos, 33612
- H Lee Moffitt Cancer Center and Research Institute I
-
West Palm Beach, Florida, Estados Unidos, 33401
- Florida Cancer Specialists & Research Institute (FCS) - Atlantis
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago
-
Niles, Illinois, Estados Unidos, 60714
- Illinois Cancer Specialists
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Comprehensive Cancer Center
-
Ypsilanti, Michigan, Estados Unidos, 48197
- St. Joseph Mercy Hospital
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55901
- Mayo Clinic - Rochester
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- University Of Nebraska Medical Center
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Astera Cancer Care
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Astera Cancer Center
-
Freehold, New Jersey, Estados Unidos, 07728
- Regional Cancer Care Associates-Freehold
-
Little Silver, New Jersey, Estados Unidos, 07739
- Regional Cancer Care Associates LLC - Little Silver
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87131-0001
- New Mexico Cancer Care Alliance
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, Estados Unidos, 10021
- Weill Cornell Medicine-New York Presbyterian Hospital
-
New York, New York, Estados Unidos, 10032
- Columbia U - Herbert Irving Comprehensive Cancer Center
-
Nyack, New York, Estados Unidos, 10960
- Hematology Oncology Associates of Rockland, P.C.
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28806
- Messino Cancer Center
-
Concord, North Carolina, Estados Unidos, 28205
- Levine Cancer Institute - Concord
-
Pinehurst, North Carolina, Estados Unidos, 28374
- FirstHealth of the Carolinas
-
Wilson, North Carolina, Estados Unidos, 27895
- Regional Medical Oncology Center
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- Gabrail Cancer Center Research
-
Cincinnati, Ohio, Estados Unidos, 45236
- Oncology Hematology Care (OHC), Inc. - Kenwood Office
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Willamette Valley Cancer Institute and Research Center - Oncology
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15524
- Western Pennsylvania Hospital Hematology & Cellular Therapy
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Amarillo, Texas, Estados Unidos, 79124
- Texas Oncology - Amarillo
-
Austin, Texas, Estados Unidos, 78705
- Texas Oncology-Austin Midtown
-
Dallas, Texas, Estados Unidos, 75246
- Texas Oncology-Baylor Charles A. Sammons Cancer Center
-
Dallas, Texas, Estados Unidos, 75230
- Texas Oncology - Medical City Dallas Pediatric Hematology
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas MD Anderson Cancer Center
-
Houston, Texas, Estados Unidos, 77090
- Millennium Physicians - Oncology
-
Plano, Texas, Estados Unidos, 75075
- Texas Oncology
-
San Antonio, Texas, Estados Unidos, 78229
- Mays Cancer Center
-
Tyler, Texas, Estados Unidos, 75702
- USO Texas Oncology - Tyler
-
Tyler, Texas, Estados Unidos, 75701
- UT Health East Texas HOPE Cancer Center - Tyler
-
Weslaco, Texas, Estados Unidos, 78596
- Texas Oncology- Weslaco
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Utah Cancer Specialists/ IHO Corp
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute; The University of Utah
-
-
Virginia
-
Gainesville, Virginia, Estados Unidos, 22155
- Virginia Cancer Specialists
-
Roanoke, Virginia, Estados Unidos, 24014
- Oncology and Hematology Associates of Southwest Virginia Inc.
-
-
West Virginia
-
Wheeling, West Virginia, Estados Unidos, 26003
- Wheeling Hospital
-
-
-
-
-
Angers, França
- Centre Hospitalier Universitaire D'Angers - Hématologie Clinique
-
Besançon, França, 25000
- CHRU de Besançon- Hopital Jean Minjoz
-
Clermont-Ferrand, França, 63000
- CHU de Clermont-Ferrand, site Estaing
-
Lens, França
- Centre Hospitalier Docteur Schaffner
-
Nantes, França, 44202
- L'Hôpital Privé Confluent
-
Nantes, França
- L'hôpital Privé du Concluent
-
Paris, França, 75010
- Hopital Saint Louis
-
Poitiers, França
- Centre Hospitalier Universitaire de Poitiers
-
Périgueux, França
- Centre Hospitalier - Hôpital de jour d'Hématologie
-
Vandœuvre-lès-Nancy, França, 54511
- CHU de Nancy Brabois
-
Vannes, França, 56017
- Centre Hospitalier Bretagne Atlantique
-
Villejuif, França
- Institut Gustave Roussy
-
-
Aquitaine
-
Pessac, Aquitaine, França, 33600
- Centre Hospitalier Universitaire de Bordeaux-Hopital du Haut Leveque
-
-
Brittany Region
-
Brest, Brittany Region, França, 29609
- CHRU Brest Hôp Morvan
-
-
Gironde
-
Bordeaux, Gironde, França, 33000
- Institut Bergonie
-
-
Haut-Rhin
-
Mulhouse, Haut-Rhin, França, 68100
- Centre Hosp Mulh Hop Emile Muller
-
-
Haute-Normandie
-
Rouen, Haute-Normandie, França, 76038
- Centre Henri Becquerel
-
-
Haute-Vienne
-
Limoges, Haute-Vienne, França, 87042
- CHU de Limoges Dupuytren
-
-
Isere
-
La Tronche, Isere, França, 38700
- CHU de Grenoble - Hopital Albe
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, França, 44000
- CHU de Nantes - Hematologie
-
-
Nord
-
Lille, Nord, França, 59037
- CHRU de Lille Hop Claude Huriez
-
-
Sarthe
-
Le Mans, Sarthe, França, 72000
- Centre Hospitalier Le Mans
-
-
Île-de-France Region
-
Créteil, Île-de-France Region, França, 94010
- Hopital Henri Mondor - Hemopathies Lymphoides
-
-
-
-
-
Budapest, Hungria, 1122
- Országos Onkológiai Intézet
-
Budapest, Hungria, 1088
- Semmelweis Egyetem Általános Orvostudományi Kar
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hungria, 4032
- Debreceni Egyetem Klinikai Központ
-
-
-
-
-
Brescia, Itália, 25123
- ASST Spedali Civili di Brescia
-
Catania, Itália, 95122
- PO Garibaldi-Nesima, ARNAS Garibaldi
-
Florence, Itália, 50134
- AOU Careggi
-
Lecce, Itália
- Ospedale Vito Fazzi, ASL Lecce
-
Milan, Itália
- Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda
-
Milan, Itália
- IEO - Istituto Europeo di Oncologia, IRCCS
-
Milan, Itália
- Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
-
Monza, Itália
- Ospedale San Gerardo, ASST di Monza
-
Pescara, Itália
- Ospedale Civile S.Spirito, PO di Pescara, AUSL Pescara
-
Rimini, Itália
- Ospedale Infermi di Rimini, AUSL Rimini, Distretto di Rimini, Presidio di Rimini, Santarcangelo di Romagna e Novafeltria
-
Roma, Itália, 00168
- Catholic University Of Sacred Heart
-
Roma, Itália
- PU Campus Bio-Medico di Roma
-
Roma, Itália
- Regina Elena, Istituto Nazionale dei Tumori , IFO, IRCCS
-
Terni, Itália, 05100
- Azienda Ospedaliera Santa Maria di Terni
-
Torino, Itália
- Azienda Ospedaliera Ordine Mauriziano di Torino, Ospedale Umberto I di Torino
-
Treviso, Itália
- Ospedale S.Giacomo Apostolo, PO Castelfranco Veneto, AULSS 2 Marca Trevigiana
-
Trieste, Itália
- Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), Ospedale Maggiore
-
-
Campania
-
Naples, Campania, Itália, 80122
- AOU Federico II
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Itália, 47014
- Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS
-
-
-
-
-
Katowice, Polônia
- Pratia Onkologia Katowice
-
Krakow, Polônia, 30-727
- Pratia MCM Krakow
-
Torun, Polônia, 87-100
- MICS Centrum Medyczne Torun
-
Warsaw, Polônia
- MTZ Clinical Research powered by Pratia
-
Wroclaw, Polônia, 50-367
- Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu
-
-
Greater Poland Voivodeship
-
Skórzewo, Greater Poland Voivodeship, Polônia, 60-185
- Centrum Medyczne Pratia Poznan
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polônia, 02-781
- Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
-
-
-
-
-
Bebington, Reino Unido
- The Clatterbridge Cancer Centre NHS Foundation Trust - Clatterbridge Cancer Centre
-
Cornwell, Reino Unido
- Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
-
Glasgow, Reino Unido, G12 0YN
- Beatson West of Scotland Cancer Centre
-
Middlesex, Reino Unido
- Northwick Park Hospital Middlesex, United Kindgom, HA1 3UJ
-
-
Edinburgh, City of
-
Edinburgh, Edinburgh, City of, Reino Unido, EH4 2XU
- Western General Hospital - Haematology
-
-
London City
-
London, London City, Reino Unido, W12 0HS
- Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
-
London, City of
-
London, London, City of, Reino Unido, EC1A 7BE
- St Bartholomew's Hospital Barts Health NHS Trust
-
-
-
-
-
Hualien City, Taiwan
- Buddihist Tzu Chi Medical Foundation- Hualien Tzu Chi Hospital
-
Kaohsiung City, Taiwan, 833
- Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
-
-
-
Ankara, Turquia (Türkiye)
- Gazi University Medical Faculty
-
Ankara, Turquia (Türkiye)
- Ankara University Medical Faculty - Hematology
-
Ankara, Turquia (Türkiye)
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research
-
Istanbul, Turquia (Türkiye)
- Medipol Bagcilar Mega Hospital
-
Samsun, Turquia (Türkiye)
- Ondokuz Mayis University Medical Faculty - Hematology
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Have voluntarily agreed to provide written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol.
-
Males or females are ≥18 years of age, or per country adult legal age regulations, at the time of providing voluntary written informed consent.
-
Life expectancy ≥3 months before enrollment.
-
Meet requirement for hepatitis and human immunodeficiency virus (HIV) infection as follows
- Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic hepatitis B virus (HBV) infection Note: Participants whose HBV infection status could not be determined by serologic test results have to be negative for HBV-DNA by PCR to be eligible for study participation. Participants seropositive for HBV with undetectable HBV DNA by PCR are permitted with appropriate antiviral prophylaxis.
- Negative test results for hepatitis C virus (HCV) Note: Participants who are positive for HCV antibody must be negative for HCV RNA by PCR to be eligible for study participation
- If HIV positive, HIV infection is controlled. Based on Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections - Guidance for Industry (https://www.fda.gov/media/121319/download), patients with HIV should be considered eligible if they have CD4+ T-cell counts ≥ 350 cells/uL and in general, if they have not had an opportunistic infection within the past 12 months. Other exclusion criteria should be considered regarding the drug-drug interaction if antiviral drugs are used. Therefore, in case of controlled HIV infection, since antiviral drugs are used, trial patients should be on established ART for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrolment.
-
Have histologically confirmed FL, Grades 1 to 3A.
-
Must have been previously treated with at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy:
a. Systemic therapy includes treatments such as:
i. Rituximab monotherapy
ii. Chemotherapy given with or without rituximab
iii. Radioimmunoconjugates such as 90Y-ibritumomab tiuxetan and 131I-tositumomab.
b. Systemic therapy does not include, for example:
i. Local involved field radiotherapy for limited-stage disease
ii. Helicobacter pylori eradication
c. Prior investigational therapies will be allowed provided the subject has received at least 1 prior systemic therapy as discussed in Inclusion Criterion #6a.
d. Prior autologous/allogeneic hematopoietic stem cell transplant (HSCT) will be allowed.
e. Prior chimeric antigen receptor T-cell therapy (CAR T) will be allowed.
-
Must have documented relapsed, refractory, or PD after treatment with systemic therapy (refractory defined as less than PR or disease progression <6 months after last dose).
-
Have measurable disease as defined by the Lugano Classification (Cheson, 2014; Appendix 5).
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
-
Within 7 days prior to randomization, all clinically significant toxicity related to a prior anticancer treatment (ie, chemotherapy, immunotherapy, and/or radiotherapy must have either resolved to Grade 1 per NCI CTCAE Version 5.0 OR are clinically stable and no longer clinically significant.
-
Have provided sufficient tumor tissue block or unstained slides for EZH2 mutation testing in all subjects to allow for stratification
a. If EZH2 mutation status is known from site-specific testing, subjects can be enrolled. Tumor tissue will be required for confirmatory testing of EZH2 status at study-specific laboratories. If the archival tumor sample was collected more than 24 months prior to the anticipated administration of the first dose (cycle 1 day 1), then a fresh biopsy must be provided. Fresh tumor biopsy is appropriate except for procedures deemed to result in unacceptable risk because of the anatomical location including brain, lung/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel. Archival tumor biopsy sections mounted on slides are also acceptable.
NOTE: Confirmatory testing will also be performed for Stage 1, if local EZH2 testing is conducted, unless there is insufficient tumor tissue to perform testing after discussion with the Sponsor's or Designee Medical Monitor.
-
Time between prior anticancer therapy and first dose of tazemetostat as follows:
- Cytotoxic chemotherapy - At least 21 days.
- Noncytotoxic chemotherapy (eg, small molecule inhibitor) - At least 14 days.
- Nitrosoureas - At least 6 weeks.
- Monoclonal and/or bispecific antibodies or CAR T - At least 28 days.
- Radiotherapy - At least 6 weeks from prior radioisotope therapy; at least 12 weeks from 50% pelvic or total body irradiation.
-
Adequate renal function defined as calculated creatinine clearance ≥30 mL/minute per the Cockcroft and Gault formula.
-
Adequate bone marrow function:
a. Absolute neutrophil count (ANC) ≥1000/mm3 (≥1.0 × 10^9/L) if no lymphoma infiltration of bone marrow OR ANC ≥750/mm3 (≥75 × 10^9/L) with bone marrow infiltration
-
Without growth factor support (filgrastim or pegfilgrastim) for at least 14 days.
b. Platelets ≥75,000/mm3 (≥75 × 10^9/L)
-
Evaluated at least 7 days after last platelet transfusion.
c. Hemoglobin ≥9.0 g/dL
-
May receive transfusion
-
-
Adequate liver function:
- Total bilirubin ≤1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome.
- Alkaline phosphatase (ALP) (in the absence of bone disease), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN if subject has liver infilration).
-
International normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (aPTT) ≤1.5 × ULN (unless on warfarin, then INR ≤3.0). In subjects with thromboembolism risk, prophylactic anticoagulation, or antiplatelet therapy at investigator discretion is recommended.
-
Females of childbearing potential (FCBP) must have a negative urine or serum pregnancy tests (beta-human chorionic gonadotropin [β-hCG] tests with a minimum sensitivity of 25 mIU/mL or equivalent units of β-hCG) at screening within 10 to 14 days prior to first dose of study drug. The subject may not receive study drug until the study doctor has verified that the results of pregnancy tests are negative. All females will be considered to be of childbearing potential unless they are naturally postmenopausal (at least 24 months consecutively amenorrhoeic [amenorrhea following cancer therapy does not rule out childbearing potential] and without other known or suspected cause) or have been sterilized surgically (ie, total hysterectomy and/or bilateral oophorectomy, with surgery completed at least 1 month before dosing).
-
Females of childbearing potential (FCBP) enrolled must either practice complete abstinence or agree to use two reliable methods of contraception simultaneously. This includes ONE highly effective method of contraception and ONE additional effective contraceptive method. Contraception must begin at least 28 days prior to first dose of study drug, continue during study treatment (including during dose interruptions), and for 12 months after study drug discontinuation. Female subjects must also refrain from breastfeeding for 12 months following last dose of study drug. If the below contraception methods are not appropriate for the FCBP, she must be referred to a qualified contraception provider to determine the medically effective contraception method appropriate for the subject. The following are examples of highly effective and additional effective methods of contraception:
Examples of highly effective methods:
- Intrauterine device (IUD)
- Hormonal (ovulation inhibitory combined [estrogen and progesterone] birth control pills or intravaginal/transdermal system, injections, implants, levonorgestrel-releasing intrauterine system [IUS], medroxyprogesterone acetate depot injections, ovulation inhibitory progesterone-only pills [e.g. desogestrel]) NOTE: There is a potential for tazemetostat interference with hormonal contraception methods due to enzymatic induction.
- Bilateral tubal ligation
- Partner's vasectomy (if medically confirmed [azoospermia] and sole sexual partner).
Examples of additional effective methods:
- Male latex or synthetic condom,
- Diaphragm,
- Cervical Cap
NOTE: Female subjects of childbearing potential exempt from these contraception requirements are subjects who practice complete abstinence from heterosexual sexual contact. True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or post ovulation methods) and withdrawal are not acceptable methods of contraception.
-
All study participants enrolled must be registered into the applicable pregnancy prevention program (e.g. REVLIMID REMS in the US, Pregnancy Prevention Programme [PPP] in Europe) for lenalidomide to be administered and be willing and able to comply with the requirements of the applicable program as appropriate for the country in which the drug is being used.
a. Female subjects of childbearing potential (FCBP) must adhere to the scheduled pregnancy testing as required in theapplicable pregnancy prevention program. During study treatment, FCBP must agree to have pregnancy testing weekly for the first 28 days of study participation and then every 28 days for FCBP with regular or no menstrual cycles OR every 14 days for FCBP with irregular menstrual cycles. FCBP must also have a pregnancy test at end of lenalidomide treatment, at day 14 (for FCBP with irregular menstrual cycles) and day 28 following the last dose of lenalidomide and at overall treatment discontinuation (at the End-of-Treatment/30-day safety Follow-up visit). Female subjects exempt from this requirement are subjects who have been naturally postmenopausal for at least 24 consecutive months OR are surgically sterilized (ie, total hysterectomy or bilateral oophorectomy) with surgery at least 1 month before the first dose of study treatment.
-
Male subjects must either practice complete abstinence or agree to use a latex or synthetic condom, even with a successful vasectomy (medically confirmed azoospermia), during sexual contact with a pregnant female or FCBP from first dose of study drug, during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation.
NOTE: Male subjects must not donate semen or sperm from first dose of study drug, during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation.
Exclusion Criteria:
All Subjects
-
Prior exposure to tazemetostat or other inhibitor(s) of EZH2.
-
Prior exposure to lenalidomide or drugs of the same class.
-
Grade 3b, mixed histology, or FL that has histologically transformed to diffuse large B-cell lymphoma (DLBCL) (subjects transformed from DLBCL to FL may be enrolled).
-
Has thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE Version 5.0 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN).
-
Has a prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) or B-cell acute lymphoblastic leukemia (B-ALL).
-
Subjects with uncontrolled leptomeningeal metastases or brain metastases or history of previously treated brain metastases.
-
Subjects taking medications that are known strong CYP3A inhibitors and strong or moderate CYP3A inducers (including St. John's wort).
-
Are unwilling to exclude grapefruit juice, Seville oranges, and grapefruits from the diet and/or consumed within 1 week of the first dose of study drug and for the duration of the study.
-
Major surgery within 4 weeks before the first dose of study drug.
a. Note: Minor surgery (eg, minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 3 weeks prior to enrollment.
-
Are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat.
-
Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia.
-
Prolongation of corrected QT interval using Fridericia's formula (QTcF) to ≥480 msec at screening or history of long QT syndrome.
-
Venous thrombosis or pulmonary embolism within the last 3 months before starting tazemetostat.
a. Note: Participants who have experienced deep vein thrombosis/pulmonary embolism more than 3 months before enrollment are eligible but are recommended to receive prophylaxis.
-
Have an active infection requiring systemic therapy.
-
Known hypersensitivity to any component of tazemetostat or lenalidomide; known severe hypersensitivity to any component of rituximab requiring hospitalization or resuscitation.
-
Active viral infection with or seropositive for HBV: HBV surface antigen (HBsAg) positive OR HBsAg negative, anti-HBs positive and/or anti-HBc positive with detectable HBV DNA.
NOTE: Subjects who are HBsAg negative, anti-HBs positive and/or anti-HBc positive, but with undetectable viral DNA and normal ALT are eligible. Subjects who are seropositive due to HBV vaccination (HBsAg negative, HBV surface antibody [anti-HBs] positive, and HBV core antibody [anti-HBc] negative) are eligible.
-
Active viral infection with hepatitis C virus (as measured by positive HCV antibody and detectable viral RNA, HIV), or known active infection with human T-cell lymphotropic virus.
NOTE: Subjects with a history of hepatitis C infection (HCV antibody reactive) who have normal ALT and undetectable HCV RNA are eligible.
-
Any other medical or social condition that, in the Investigator's judgment, will interfere with a participant's ability to provide informed consent, to receive study drugs, or meet study demands, or that substantially increases the risk associated with the subject's participation in the study, or that may interfere with interpretation of results.
-
Female subjects who are pregnant or lactating/breastfeeding.
-
Subjects who have undergone a solid organ transplant.
-
Subjects with malignancies other than FL. a. Exception: Subjects with another malignancy who have been disease-free for 3 years, or subjects with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Tazemetostat + R2 arm
Stage 1 (Phase 1b): completed
Stage 2:
Maintenance Therapy (Stages 1&2): Tazemetostat 800mg PO BD dose for up to 2 years after the initial 12 months of combination therapy. Following an Independent Data Monitoring Committee review, an urgent safety measure was implemented and administration of tazemetostat was permanently discontinued. No further investigational treatment is administered. Participants previously exposed to tazemetostat enter protocol-specified long-term safety follow-up |
Stage 1 (Phase 1b): Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy. Following implementation of the urgent safety measure, tazemetostat administration was discontinued. No further dosing is performed.
Outros nomes:
Stage 2: Tazemetostat 800 mg administered orally twice daily in continuous 28-day cycles for 12 cycles. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy.
Outros nomes:
Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles. Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5. |
|
Comparador de Placebo: Placebo + R2 Arm
Participants were assigned to receive placebo in combination with lenalidomide and rituximab. Following implementation of the urgent safety measure, placebo administration was permanently discontinued. No further investigational treatment is administered. Stage 2:
Maintenance Therapy (Stage 2): Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy. During maintenance, placebo will be continued until disease progression or unacceptable toxicity, or participant withdraws consent. |
Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles. Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5. Stage 2: Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy. Following implementation of the urgent safety measure, placebo administration was discontinued. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase 1b: Recommended Phase 3 Dose (RP3D) of tazemetostat in combination with rituximab and lenalidomide (R2)
Prazo: Subjects are evaluated for DLTs during the first 28-day cycle. The RP3D for Phase 3 was selected at the end of Stage 1
|
The safety and tolerability of tazemetostat in combination with R2 in subjects with R/R FL were evaluated. RP3D of tazemetostat for further evaluation in phase 3 was selected as assessed by the occurrence of treatment-emergent dose-limiting toxicities (DLTs) and adverse events (AEs). |
Subjects are evaluated for DLTs during the first 28-day cycle. The RP3D for Phase 3 was selected at the end of Stage 1
|
|
Phase 3: Progression-Free Survival (PFS) in the Intent-to-treat wild-type (ITT-WT) populations
Prazo: Stage 2: Up to 72 months
|
PFS is defined as the time from the date of randomization to the time of confirmed disease progression per the 2014 Lugano Classification or death, whichever occurs first, as assessed by Investigators. PFS will be assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further efficacy data are collected, and any post-urgent safety measure analyses are descriptive in nature. |
Stage 2: Up to 72 months
|
|
Phase 3: PFS in the Intent-to-treat mutant-type (ITT-MT) population
Prazo: Stage 2: Up to 72 months
|
PFS is defined as the time from the date of randomization to the time of confirmed disease progression per the 2014 Lugano Classification or death, whichever occurs first, as assessed by Investigators. |
Stage 2: Up to 72 months
|
|
Phase 3: PFS in the R/R FL population regardless of mutation status by Investigator assessment
Prazo: Stage 2: Up to 72 months
|
PFS is defined as the time from the date of randomization to the first observation of documented objective disease progression per the 2014 Lugano Classification or death due to any cause, whichever occurs first. PFS is defined as the time from the date of randomization to the time of confirmed disease progression per the 2014 Lugano Classification or death, whichever occurs first, as assessed by Investigators. |
Stage 2: Up to 72 months
|
|
Phase 3: Progression-Free Survival (PFS) in the all comer (ITT-All) populations.
Prazo: Stage 2: Up to 72 months
|
PFS is defined as the time from the date of randomization to the time of confirmed disease progression per the 2014 Lugano Classification or death, whichever occurs first, as assessed by Investigators. PFS will be assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further efficacy data are collected, and any post-urgent safety measure analyses are descriptive in nature. |
Stage 2: Up to 72 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase 1b: PK of tazemetostat, EPZ 6930 (desethyl metabolite), and lenalidomide as data permit: Time to Maximum Observed Drug Concentration (Tmax)
Prazo: Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
|
|
Phase 1b: PK of tazemetostat: area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration [AUC(0-t)],
Prazo: Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
|
|
Phase 1b: PK of tazemetostat: area under the plasma concentration-time curve (AUC) from time 0 to infinity [AUC(0-∞)]
Prazo: Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
|
|
Phase 1b: The apparent terminal elimination half-life (t1/2) of tazemetostat, EPZ 6930 (desethyl metabolite), and lenalidomide as data permit
Prazo: Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
|
|
Phase 3: OS in the ITT-MT population
Prazo: Stage 2: Up to 96 months
|
Stage 2: Up to 96 months
|
|
|
Phase 3: OS in the R/R FL population regardless of mutation status
Prazo: Stage 2: Up to 96 months
|
Stage 2: Up to 96 months
|
|
|
Phase 3: PFS in the ITT-WT population, assessed by a blinded IRC
Prazo: Stage 2: Up to 96 months
|
Stage 2: Up to 96 months
|
|
|
Phase 3: PFS in the ITT-MT population, assessed by a blinded IRC
Prazo: Stage 2: Up to 96 months
|
Stage 2: Up to 96 months
|
|
|
Phase 3: PFS in the R/R FL population regardless of mutation status, assessed by a blinded IRC
Prazo: Stage 2: Up to 96 months
|
Stage 2: Up to 96 months
|
|
|
Phase 1b: Pharmacokinetics (PK) of tazemetostat: Maximum (peak) Observed Plasma Drug Concentration (Cmax).
Prazo: Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
Cmax will be recorded from the PK blood samples collected. |
Stage 1: In cycles 1 and 2 on days 1 and 15 (28 days cycle)
|
|
Phase 3: Complete Response Rate (CRR) in ITT-WT population
Prazo: Stage 2: Up to 96 months
|
CRR is defined as the proportion of participants achieving CR according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded Independent Review Committee (IRC). CRR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: CRR in ITT-MT population
Prazo: Stage 2: Up to 96 months
|
CRR is defined as the proportion of participants achieving CR according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC. CRR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: CRR in the Relapsed/Refractory (R/R) Follicular Lymphoma (FL) population regardless of mutation status
Prazo: Stage 2: Up to 96 months
|
CRR is defined as the proportion of participants achieving CR according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC. CRR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: Objective Response Rate (ORR) in the ITT-WT population
Prazo: Stage 2: Up to 96 months
|
ORR is defined as the proportion of participants achieving a best overall response (BOR) of partial response (PR) or complete response (CR) according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC. ORR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: ORR in the ITT-MT population
Prazo: Stage 2: Up to 96 months
|
ORR is defined as the proportion of participants achieving a best overall response (BOR) of partial response (PR) or complete response (CR) according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC. ORR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: ORR in the R/R FL population regardless of mutation status
Prazo: Stage 2: Up to 96 months
|
ORR is defined as the proportion of participants achieving a best overall response (BOR) of partial response (PR) or complete response (CR) according to the 2014 Lugano Classification, as assessed by the Investigator and a blinded IRC. ORR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: Overall Survival (OS) in the ITT-WT population
Prazo: Stage 2: Up to 96 months
|
OS is defined as the time from the date of randomization until death due to any cause. |
Stage 2: Up to 96 months
|
|
Phase 3: Duration Of Response (DOR) in the ITT-WT population
Prazo: Stage 2: Up to 96 months
|
DOR is defined as the time from initial CR or PR to documented progression or death due to any cause, whichever occurs first, for those participants with a CR or PR, as assessed by the Investigator and by a blinded IRC. DOR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: DOR in the ITT-MT population
Prazo: Stage 2: Up to 96 months
|
DOR is defined as the time from initial CR or PR to documented progression or death due to any cause, whichever occurs first, for those participants with a CR or PR, as assessed by the Investigator and by a blinded IRC. DOR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: DOR in the R/R FL population regardless of mutation status
Prazo: Stage 2: Up to 96 months
|
DOR is defined as the time from initial CR or PR to documented progression or death due to any cause, whichever occurs first, for those participants with a CR or PR, as assessed by the Investigator and by a blinded IRC. DOR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: Disease Control Rate (DCR) in the ITT-WT population
Prazo: Stage 2: Up to 96 months
|
DCR, defined as the proportion of participants with best overall response of CR, PR, or stable disease (SD) lasting 12 or more months, as assessed by the Investigator and by a blinded IRC. DCR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: DCR in the ITT-MT population
Prazo: Stage 2: Up to 96 months
|
DCR, defined as the proportion of participants with best overall response of CR, PR, or stable disease (SD) lasting 12 or more months, as assessed by the Investigator and by a blinded IRC. DCR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
Phase 3: DCR in the R/R FL population regardless of mutation status
Prazo: Stage 2: Up to 96 months
|
DCR, defined as the proportion of participants with best overall response of CR, PR, or stable disease (SD) lasting 12 or more months, as assessed by the Investigator and by a blinded IRC. DCR is assessed based on data collected prior to treatment discontinuation as a result of the urgent safety measure. Following implementation of the urgent safety measure, no further response assessments are performed, and analyses are descriptive in nature. |
Stage 2: Up to 96 months
|
|
PK parameters will be summarized by plasma concentrations of tazemetostat and lenalidomide descriptively.
Prazo: Stage 2: In cycles 2, 4, 6, and 12 at Day 1 (28 days cycle)
|
PK assessments will be conducted on samples collected until the urgent safety measure. No further PK analyses are performed post-urgent safety measure. |
Stage 2: In cycles 2, 4, 6, and 12 at Day 1 (28 days cycle)
|
|
Percentage of Participants Experiencing Adverse Events (AEs)
Prazo: Up to 36 months
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
Up to 36 months
|
|
Percentage of Participants with Clinically Significant Changes in Physical Examination
Prazo: Up to 36 months
|
Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be graded by the investigator according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE) Version 5.0. |
Up to 36 months
|
|
Percentage of Participants with Clinically Significant Changes in Vital Signs
Prazo: Up to 36 months
|
Percentage of participants with clinically significant changes in vital signs findings will be reported. The clinical significance will be graded by the investigator according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE) Version 5.0. |
Up to 36 months
|
|
Percentage of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Readings
Prazo: Up to 72 months
|
Percentage of participants with clinically significant changes in ECG Readings will be reported. The clinical significance will be graded by the investigator according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE) Version 5.0. |
Up to 72 months
|
|
Performance status evaluated by Eastern Cooperation Oncology Group (ECOG)
Prazo: Up to 72 months
|
ECOG is a 6-point performance status scale used to assess performance using PA as a key indicator (e.g., 0 = fully active, 2 = up and about more than 50% of walking hours, 5 = dead) Performance status will be assessed per usual clinical practice and will be recorded in the medical record. |
Up to 72 months
|
|
Duration of Study Drug Exposure
Prazo: Up to 36 months
|
Study drug exposure reflects administration prior to implementation of the urgent safety measure. No further investigational drug exposure occurs post-urgent safety measure. |
Up to 36 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Ipsen Medical Director, Ipsen
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma Não-Hodgkin
- Linfoma
- Doenças hemic e linfáticas
- Linfoma Folicular
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Ácidos carboxílicos
- Piperidinas
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Anticorpos, monoclonais, derivados de murinos
- Ftalimidas
- Ácidos ftaléticos
- Ácidos, carbocíclicos
- Piperidones
- Isoindoles
- Lenalidomida
- Rituximabe
- Tazemetostat
Outros números de identificação do estudo
- EZH-302
- 2019-003333-42 (Número EudraCT)
- 2024-510690-16-00 (Ctis)
- 2019 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Prazo de Compartilhamento de IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Critérios de acesso de compartilhamento IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .